On the stock market since 2022, it operates in the world of health and science. It has 1,770 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
An average decline of 16% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
Sales run at $449.7M a year. A small number, but proof the product has real buyers.
A loss of $25.8M against $449.7M in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
The stock trades 32% above the average analyst price target.
On our five-subject report card, ZIMV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ZIMV is a high-risk stock — not yet profitable, and its future rides on its product catching on.